-
1.发明申请公开(公告)号：US20120144334A1
公开(公告)日：2012-06-07
申请号：US12959120
申请日：2010-12-02
Applicant: John Paul Reichert
Inventor： John Paul Reichert
IPC: G06F3/048
CPC classification number: G06Q10/087
Abstract: A method in a warehouse management system for providing instructions to a user, comprising: receiving a table in a database of the warehouse management system, the table defining the instructions, one or more of the columns of the table containing data and image references pertaining to respective warehouse storage items associated with the instructions; adding an expression column to the table, the expression column for defining a combination of the data and image references pertaining to the respective warehouse storage items in accordance with the instructions; adding markup language code to the expression column for customizing a graphical presentation of the combination; generating the graphical presentation of the combination from the markup language code; and, displaying the graphical presentation on a display screen of the warehouse management system, thereby providing the instructions to the user in a graphical format.
Abstract translation: 一种用于向用户提供指令的仓库管理系统中的方法，包括：在仓库管理系统的数据库中接收表格，定义所述指令的表格，所述表格中的一列或多列包含与 与指令相关的各仓库存货; 向表中添加表达式列，用于根据指令定义与各个仓库存储项目有关的数据和图像引用的组合的表达式列; 在表达式列中添加标记语言代码，用于自定义组合的图形表示; 从标记语言代码生成组合的图形呈现; 以及在仓库管理系统的显示屏幕上显示图形呈现，从而以图形格式向用户提供指令。
-
公开(公告)号：US07722718B2
公开(公告)日：2010-05-25
申请号：US11873831
申请日：2007-10-17
Applicant: Jessie English , Thierry Oliver Fischmann , Thomas Hesson , Alan William Hruza , Weihong Jin , Paul Reichert , Catherine Smith , Shahriar Shane Taremi
Inventor： Jessie English , Thierry Oliver Fischmann , Thomas Hesson , Alan William Hruza , Weihong Jin , Paul Reichert , Catherine Smith , Shahriar Shane Taremi
CPC classification number: C12N9/1205 , C07K2299/00
Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
Abstract translation: 本发明涉及ERK2多肽的结晶及其复合物，其特别用于结构辅助药物设计。
-
3.发明授权Crystalline form of the catalytic domain of Aurora 2 kinase and methods of use thereof 失效Aurora 2激酶催化结构域的结晶形式及其使用方法公开(公告)号：US07422885B1
公开(公告)日：2008-09-09
申请号：US10943438
申请日：2004-09-17
Applicant: Thierry O. Fischmann , Vincent S. Madison , Alan William Hruza , Paul Reichert , Lata Ramanathan , David Paul Sanden , Wolfgang Seghezzi
Inventor： Thierry O. Fischmann , Vincent S. Madison , Alan William Hruza , Paul Reichert , Lata Ramanathan , David Paul Sanden , Wolfgang Seghezzi
CPC classification number: C12N9/12
Abstract: The present invention discloses nucleic acids that encode an active human Aurora 2 kinase catalytic domain. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active human Aurora 2 kinase catalytic domain. The present invention further discloses a crystalline form of a catalytic domain of human Aurora 2 kinase. In addition, the present invention discloses methods of using the X-ray diffractable crystals of human Aurora 2 kinase in structure assisted drug design to identify compounds that can modulate the enzymatic activity of human Aurora 2 kinase.
Abstract translation: 本发明公开了编码活性人Aurora 2激酶催化结构域的核酸。 本发明还公开了生长包含活性人Aurora 2激酶催化结构域的多肽的X射线衍射晶体的方法。 本发明还公开了人Aurora 2激酶的催化结构域的结晶形式。 此外，本发明公开了在结构辅助药物设计中使用人Aurora 2激酶的X射线衍射晶体的方法来鉴定可调节人Aurora 2激酶的酶活性的化合物。
-
4.发明授权Crystalline form of an n231 mutant catalytic domain of ADAM33 and methods of use thereof 失效ADAM33的n231突变体催化结构域的结晶形式及其使用方法公开(公告)号：US07285408B2
公开(公告)日：2007-10-23
申请号：US10741208
申请日：2003-12-19
Applicant: Peter Orth , Paul Reichert , Vincent S. Madison , Wenyan Wang , Jun Zou
Inventor： Peter Orth , Paul Reichert , Vincent S. Madison , Wenyan Wang , Jun Zou
CPC classification number: C12N9/6489 , A61K38/00 , C07K2299/00 , Y02A90/26
Abstract: The present invention discloses purified polypeptides that comprise an active human ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active human ADAM33 catalytic domain. The present invention further discloses a crystalline form of a catalytic domain of human ADAM33. In addition, the present invention discloses methods of using the X-ray diffractable crystals of human ADAM33 in structure based drug design to identify compounds that can modulate the enzymatic activity of human ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the human ADAMS33 catalytic domain.
Abstract translation: 本发明公开了包含活性人ADAM33催化结构域的纯化多肽。 此外，本发明公开了编码本发明多肽的核酸。 本发明还公开了生长包含活性人ADAM33催化结构域的多肽的X射线衍射晶体的方法。 本发明还公开了人ADAM33的催化结构域的结晶形式。 此外，本发明公开了在基于结构的药物设计中使用人ADAM33的X射线衍射晶体的方法来鉴定可以调节人ADAM33的酶活性的化合物。 本发明还公开了通过施用治疗量的人ADAMS33催化结构域来治疗呼吸系统疾病的方法。
-
公开(公告)号：US20060088924A1
公开(公告)日：2006-04-27
申请号：US11233581
申请日：2005-09-23
Applicant: Jessie English , Thierry Fischmann , Thomas Hesson , Alan Hruza , Weihong Jin , Paul Reichert , Catherine Smith , Shahriar Taremi
Inventor： Jessie English , Thierry Fischmann , Thomas Hesson , Alan Hruza , Weihong Jin , Paul Reichert , Catherine Smith , Shahriar Taremi
CPC classification number: C12N9/1205 , C07K2299/00
Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
Abstract translation: 本发明涉及ERK2多肽的结晶及其复合物，其特别用于结构辅助药物设计。
-
Patent Agency Ranking6.发明授权Crystalline interferon alpha for pulmonary delivery and method for producing the same 失效用于肺部输送的结晶干扰素α及其制备方法
公开(公告)号：US5972331A
公开(公告)日：1999-10-26
申请号：US577585
申请日：1995-12-22
Applicant: Paul Reichert , Patricia C. Weber , Rowena F. Choudrie , Bruce O. Stuart , Tattanahalli Nagabhushan , Ashit Ganguly
Inventor： Paul Reichert , Patricia C. Weber , Rowena F. Choudrie , Bruce O. Stuart , Tattanahalli Nagabhushan , Ashit Ganguly
CPC classification number: A61K9/0078 , A61K9/1688 , C07K14/56 , A61K38/00
Abstract: A method to prepare crystalline interferon alpha suitable for aerosol formulation either for systemic or topical (inhaled) drug delivery. The bioavailable interferon is in the form of crystalline submicrometer particles having a predetermined medium diameter.
Abstract translation: 制备用于全身或局部（吸入）药物递送的气溶胶制剂的结晶干扰素α的方法。 生物可利用的干扰素是具有预定中等直径的结晶亚微米颗粒的形式。
-
公开(公告)号：US5616555A
公开(公告)日：1997-04-01
申请号：US482168
申请日：1995-06-07
Applicant: Paul Reichert , Gerald S. Hammond , Hung V. Le , Tattanahalli L. Nagabhushan , Paul P. Trotta
Inventor： Paul Reichert , Gerald S. Hammond , Hung V. Le , Tattanahalli L. Nagabhushan , Paul P. Trotta
IPC: C12P21/00 , A61K38/00 , C07K20060101 , C07K14/47 , C07K14/52 , C07K14/53 , C07K14/535 , C12N15/27 , C12R1/19 , A61K38/16 , C07K1/00 , C07K14/00 , C07K17/00
CPC classification number: C07K14/535 , Y10S930/145
Abstract: This invention provides a crystalline form of recombinant human granulocyte-macrophage colony-stimulating factor (r-h-GM-CSF) and methods for making such crystals.
Abstract translation: 本发明提供重组人粒细胞 - 巨噬细胞集落刺激因子（r-h-GM-CSF）的结晶形式及其制备方法。
-
公开(公告)号：US08679472B1
公开(公告)日：2014-03-25
申请号：US11973362
申请日：2007-10-05
Applicant: Paul Reichert , Marianna Marshall Long , Alan W. Hruza , Peter Orth , Tattanahalli L. Nagabhushan
Inventor： Paul Reichert , Marianna Marshall Long , Alan W. Hruza , Peter Orth , Tattanahalli L. Nagabhushan
CPC classification number: A61K38/212
Abstract: This application covers a novel PEGylated interferon and a novel crystalline form of interferon which are useful, inter alia, for detailed structural analysis of interferon as well as treatment and prevention of viral infections and hyperproliferative diseases such as leukemia.
Abstract translation: 该应用涵盖了新型聚乙二醇化干扰素和干扰素的新型结晶形式，其特别用于干扰素的详细结构分析以及病毒感染和过度增殖性疾病如白血病的治疗和预防。
-
9.发明授权Polynucleotides encoding soluble, stable forms of human double minute 2 polypeptides 失效编码可溶性，稳定形式的人类双分子2多肽的多核苷酸公开(公告)号：US08034907B2
公开(公告)日：2011-10-11
申请号：US12621241
申请日：2009-11-18
Applicant: Shahriar Shane Taremi , Gaolian Xie , Thomas Hesson , Jose S. Duca , Corey Strickland , William T. Windsor , Vincent S. Madison , Rumin Zhang , Paul Reichert , Yaolin Wang
Inventor： Shahriar Shane Taremi , Gaolian Xie , Thomas Hesson , Jose S. Duca , Corey Strickland , William T. Windsor , Vincent S. Madison , Rumin Zhang , Paul Reichert , Yaolin Wang
CPC classification number: C07H21/04 , C07D209/20 , C07K14/47 , C07K2299/00
Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
Abstract translation: 本发明公开了可溶性的修饰的Hdm2蛋白。 此外，本发明公开了编码本发明的修饰的Hdm2蛋白质的核酸。 本发明还提供了适用于X射线结晶分析的修饰的Hdm2蛋白晶体。 本发明还公开了使用修饰的Hdm2蛋白及其晶体鉴定，选择和/或设计可用作抗癌剂的化合物的方法。 本发明还公开了与蛋白质 - 配体复合物中的修饰的Hdm2蛋白结合的化合物。
-
公开(公告)号：US07888474B2
公开(公告)日：2011-02-15
申请号：US12723184
申请日：2010-03-12
Applicant: Thomas E. Hesson , Hung V. Le , Yao Ma , Vincent S. Madison , Anthony F. Mannarino , Paul Reichert , Gerald W. Shipps, Jr. , Corey O. Strickland , Shahriar Shane Taremi , Yaolin Wang , Rumin Zhang , Jose Duca
Inventor： Thomas E. Hesson , Hung V. Le , Yao Ma , Vincent S. Madison , Anthony F. Mannarino , Paul Reichert , Gerald W. Shipps, Jr. , Corey O. Strickland , Shahriar Shane Taremi , Yaolin Wang , Rumin Zhang , Jose Duca
IPC: C07K14/00
CPC classification number: C07K14/82 , C07K2299/00
Abstract: The present invention relates to HDM2 polypeptides and mutants thereof which are complexed with various compounds, e.g., HDM2 inhibitors.
Abstract translation: 本发明涉及与各种化合物例如HDM2抑制剂复合的HDM2多肽及其突变体。
-
-
-
-
-
-
-
-
-
Search Results
48
records
(took 0.044 seconds)
